Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker XNCR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Study of XmAb412 in Healthy Participants NCT07713485 · Not Applicable - Healthy Adult Participants XmAb412 Monoclonal Bispecific Antibody, Placebo | XNCR Xencor, Inc. | Phase 1 | Recruiting | 128 | Aug 2027 | Registry ↗ |
| Oct 30, 2026 | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis NCT06619990 · Ulcerative Colitis (UC) XmAb942, Placebo | XNCR Xencor, Inc. | Phase 1/2 | Recruiting | 270 | Dec 2027 | Registry ↗ |
| Oct 9, 2026 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors NCT06276491 · Ovarian Cancer, Endometrial Cancer XmAb541 | XNCR Xencor, Inc. | Phase 1 | Recruiting | 282 | Dec 2027 | Registry ↗ |
| Aug 13, 2026 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors NCT07593092 · Ovarian Cancer XmAb541, XmAb808 | XNCR Xencor, Inc. | Phase 1 | Recruiting | 90 | Dec 2028 | Registry ↗ |
| Aug 3, 2026 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimm… NCT07284797 · Healthy, Idiopathic Inflammatory Myopathies XmAb657 | XNCR Xencor, Inc. | Phase 1 | Recruiting | 60 | Oct 2028 | Registry ↗ |
| Aug 3, 2026 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthri… NCT07230353 · Rheumatoid Arthritis Plamotamab | XNCR Xencor, Inc. | Phase 1 | Recruiting | 68 | Jun 2028 | Registry ↗ |
| Aug 3, 2026 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma NCT05433142 · Clear Cell Renal Cell Carcinoma XmAb819 | XNCR Xencor, Inc. | Phase 1 | Recruiting | 307 | Feb 2027 | Registry ↗ |
| May 5, 2026 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients Wi… NCT05005728 · Metastatic Castration-Resistant Prostate Cancer vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib | XNCR Xencor, Inc. | Phase 2 | Completed | 72 | Jun 10, 2025 | Registry ↗ |
| Mar 13, 2026 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Pat… NCT06173505 · Nonsquamous Non-small Cell Lung Cancer Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carbo… | XNCR Xencor, Inc. | Phase 1/2 | Terminated | 28 | Dec 24, 2025 | Registry ↗ |
| Dec 2, 2025 | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis NCT06005792 · Psoriasis, Atopic Dermatitis XmAb27564, Placebo | XNCR Xencor, Inc. | Phase 1 | Terminated | 23 | Mar 22, 2024 | Registry ↗ |
| Aug 7, 2025 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With… NCT05585034 · Head and Neck Squamous Cell Carcinoma, Melanoma Excluding U… XmAb®808, Keytruda® (pembrolizumab) | XNCR Xencor, Inc. | Phase 1 | Completed | 60 | May 20, 2025 | Registry ↗ |
| Feb 7, 2025 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Ma… NCT05032040 · Ovarian Cancer, Clear Cell Carcinoma vudalimab | XNCR Xencor, Inc. | Phase 2 | Active, not recruiting | 170 | Oct 15, 2025 | Registry ↗ |
| Nov 13, 2024 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressin… NCT02924402 · B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia XmAb13676 | XNCR Xencor, Inc. | Phase 1 | Completed | 154 | Apr 2024 | Registry ↗ |
| Aug 23, 2024 | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors NCT05996445 · Solid Tumors XmAb662, Keytruda® (pembrolizumab) | XNCR Xencor, Inc. | Phase 1 | Terminated | 7 | May 21, 2024 | Registry ↗ |
| Jul 5, 2024 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 · Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma XmAb®23104, Yervoy® (ipilimumab) | XNCR Xencor, Inc. | Phase 1 | Completed | 198 | Feb 15, 2024 | Registry ↗ |
| Apr 30, 2024 | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Len… NCT05328102 · Diffuse Large-cell B-cell Lymphoma Plamotamab, Tafasitamab | XNCR Xencor, Inc. | Phase 2 | Terminated | 3 | Feb 21, 2023 | Registry ↗ |
| Apr 20, 2023 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-sta… NCT04590781 · Merkel Cell Carcinoma, Small Cell Lung Cancer XmAb18087, XmAb18087 ± Pembrolizumab | XNCR Xencor, Inc. | Phase 1/2 | Terminated | 4 | Mar 24, 2022 | Registry ↗ |
| Mar 30, 2023 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advance… NCT03849469 · Melanoma, Cervical Carcinoma XmAb®22841, Pembrolizumab (Keytruda®) | XNCR Xencor, Inc. | Phase 1 | Completed | 78 | Feb 16, 2023 | Registry ↗ |
| Mar 7, 2023 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma NCT03445663 · Relapsed/ Refractory Multiple Myeloma AMG 424 | XNCR Xencor, Inc. | Phase 1 | Terminated | 27 | Jun 19, 2020 | Registry ↗ |
| Mar 1, 2023 | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers NCT04857866 · Safety in Healthy Volunteers XmAb27564, Placebo | XNCR Xencor, Inc. | Phase 1 | Completed | 48 | Nov 10, 2022 | Registry ↗ |
| Dec 1, 2022 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 · Melanoma, Breast Carcinoma XmAb20717 | XNCR Xencor, Inc. | Phase 1 | Completed | 150 | Jun 1, 2022 | Registry ↗ |
| May 10, 2022 | A Study of XmAb®18087 in Subjects With NET and GIST NCT03411915 · Neuroendocrine Tumor, Gastrointestinal Neoplasm XmAb18087 | XNCR Xencor, Inc. | Phase 1 | Completed | 62 | Oct 26, 2021 | Registry ↗ |
| Mar 8, 2022 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hemat… NCT02730312 · Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leuk… XmAb14045 | XNCR Xencor, Inc. | Phase 1 | Completed | 120 | Sep 2021 | Registry ↗ |
| Aug 20, 2019 | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus NCT02725515 · Systemic Lupus Erythematosus XmAb5871, Placebo to match XmAb5871 | XNCR Xencor, Inc. | Phase 2 | Completed | 105 | Jul 17, 2018 | Registry ↗ |
| Dec 7, 2018 | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease… NCT02725476 · IgG4-RD XmAb5871 | XNCR Xencor, Inc. | Phase 2 | Completed | 20 | Dec 2017 | Registry ↗ |
| Dec 8, 2017 | XmAb5871 Bioavailability Study NCT02867098 · Healthy Volunteers XmAb5871 | XNCR Xencor, Inc. | Phase 1 | Completed | 50 | Oct 21, 2016 | Registry ↗ |
| Jul 11, 2017 | Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 NCT02881853 · Healthy Volunteers, Atopic Disease XmAb7195, Placebo | XNCR Xencor, Inc. | Phase 1 | Completed | 57 | Feb 24, 2017 | Registry ↗ |
| Jan 24, 2017 | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History… NCT02148744 · Allergic Rhinitis, Allergic Conjunctivitis XmAb7195, Placebo | XNCR Xencor, Inc. | Phase 1 | Completed | 72 | Sep 21, 2015 | Registry ↗ |
28 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:48 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances